News & Updates

Adding percent free prostate-specific antigen (PSA) to total PSA results in better prediction of clinically significant prostate cancer and fatal prostate cancer in men, reports a study.

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.

In children with cancer receiving chemotherapy, factors such as age and susceptibility to motion sickness are associated with the risk of acute chemotherapy-induced nausea (CIN), reports a study.

Cancer patients who are being treated with chemotherapy are susceptible to chemotherapy-induced nausea and vomiting (CINV), and they continue to experience these side effects despite being administered with antiemetics, a study has shown.

Supplementation with ginseng appears to provide protective benefits against early cancer therapeutics-related cardiac dysfunction caused by doxorubicin and may help prevent early decline in left ventricular ejection fraction in patients with breast cancer, suggests a study.

Resistance exercise training counters the negative effects of androgen deprivation therapy (ADT) and improves muscle fibre size, as well as capillarization, in patients with prostate cancer, reports a study.

Immune-related adverse events (irAEs) are more likely to develop in metastatic nonsmall cell lung cancer (NSCLC) patients with certain prognostic characteristics, suggests a study. Interestingly, those who develop irAEs benefit from a much longer overall survival (OS) and time to next treatment when mitigating immortal time bias.